Floatz logo

Zanolimumab

Cutaneous T-Cell Lymphoma

Genmabmonoclonal_antibodyPhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

62 Active assets in the Cutaneous T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Cyclophosphamide
Shanghai Jiao Tong University School of Medicine
Phase 4BBB
Bexarotene
Case Comprehensive Cancer Center
Phase 4BBB
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 2BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Zanolimumab is also rated in:

T-cell non-Hodgkin lymphomaDormant
CCC
Indicative ·
52 / 100
View asset →
mycosis fungoidesDormant
CCC
Indicative ·
51 / 100
View asset →
Sezary syndromeDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →